Related Experiment Video
Updated: Jun 20, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
[Hypertension 2007-2008]
Christos Chatzikyrkou1, Jan Menne, Hermann Haller
1Abteilung für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. chatzikyrkou.christos@mh-hannover.de
Insights
Hypertension remains a major global health concern. Recent clinical trials offer new insights into managing blood pressure, impacting treatment guidelines and patient outcomes.
Area of Science:
- Cardiology and Nephrology
- Public Health and Epidemiology
Context:
- Hypertension is a leading cause of global mortality and a significant modifiable risk factor for cardiovascular, cerebrovascular, and renal diseases.
- Existing hypertension guidelines require updates due to recent large-scale clinical trial findings.
Purpose:
- To review and synthesize the implications of recent large-scale clinical trials on hypertension diagnosis and treatment.
- To highlight key findings that will significantly influence clinical practice and patient management.
Summary:
- Investigated the risks of combining angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).
- Evaluated the benefits of initiating therapy with a fixed-dose combination of a calcium channel blocker and an ACE inhibitor.
- Assessed the effectiveness of blood pressure reduction in patients over 80 years old.
- Considered the impact of newly available oral renin inhibitors on hypertension management.
Impact:
- Findings will necessitate revisions to current hypertension management guidelines.
- Clinical practice will adapt to incorporate new evidence regarding drug combinations and patient-specific therapies.
- Potential for improved patient outcomes through optimized hypertension control and novel therapeutic options.
Abstract:
Hypertension still represents a leading cause of mortality worldwide and a main modifiable risk factor for cardiovascular, cerebrovascular and renal diseases. Therefore, guideline writing groups have proposed new recommendations regarding diagnosis and treatment. Nevertheless, a series of large-scale clinical trials have been published thereafter. Their results, namely the risk associated with the combination of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), the benefits of an initial therapy with a fixed-dose combination of calcium channel blocker and ACE inhibitor, the effectiveness of blood pressure reduction in patients > 80 years, and the introduction of oral renin inhibitors in the market will enormously impact clinical practice.
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Hypertension I: Introduction
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Hypertension IV: Drug Therapy and Lifestyle Modifications